REVIEWS
899
Identification and mapping of worldwide sources of generic real-world data

906
Use of real-world evidence from healthcare utilization data to evaluate drug safety during pregnancy
K. F. Huybrechts, B. T. Bateman and S. Hernández-Díaz

ORIGINAL REPORTS
923
Methods to generate and validate a Pregnancy Register in the UK Clinical Practice Research Datalink primary care database
C. Minassian, R. Williams, W. H. Meeraus, L. Smeeth, O. M. Campbell and S. L. Thomas

934
A tool for empirical equipoise assessment in multigroup comparative effectiveness research

942
Incidence, risk factors, and outcomes of warfarin-associated major bleeding in Thai population
W. Priksri, W. Rattanavipanon, W. Saejear, K. Tanyasaensook, A. Phrommintikul, S. Chulavatnatol and S. Nathisuwan

951
Assessment of ICD-10-CM code assignment validity for case finding of outpatient anticoagulant-related bleeding among Medicare beneficiaries

965
Validity of ICD-9 and ICD-10 codes used to identify acute liver injury: A study in three European data sources

976
Identification of gastrointestinal perforation based on ICD-10 code in a Japanese administrative medical information database and associated drug exposure risk factors
M. Tanigawa, Y. Kataoka, T. Kishino, M. Kohama, Y. Uyama, Y. Suzuki and H. Yokoi

985
Determination of good pharmacovigilance reporting practices in Quebec hospital pharmacies using a modified Delphi method
P. Rault, É. Mégrourèche, J.-S. Labarre, F. Pettersen-Coulombe, D. Lebel and J.-F. Bussières

993
Zostavax vaccine effectiveness among US elderly using real-world evidence: Addressing unmeasured confounders by using multiple imputation after linking beneficiary surveys with Medicare claims

1002
Safety profile of traditional Chinese herbal injection: An analysis of a spontaneous reporting system in China
H. Li, J. Deng, L. Deng, X. Ren and J. Xia

1014
Patient-reported factors associated with the desire to continue taking sleep-inducing drugs after hospital discharge: A survey of older adults
S. Heinemann, F. Neukirchen, R. Nau, E. Hummers and W. Himmel

1023
Development and preliminary validation of an instrument to enable laypersons to assess suspected side effects from medicines
B. O'Donovan, R. M. Rodgers, A. R. Cox and J. Krska

www.pdsjournal.org

Cover image © Alexander Raths/Shutterstock
INSTRUCTIONS TO AUTHORS

Manuscript Central site—http://mc.manuscriptcentral.com/pds. New users should first create an account. Once a user is logged onto the site, submissions should be made via the 'Author Centre'.

The Editor-in-Chief should be contacted to begin this process. Papers from Asia, Africa, the Middle East, and Oceania will be handled by:

Vincent Lo Re
Co-Director, Clinical Core, Penn Center for AIDS Research, Perelman School of Medicine, University of Pennsylvania, Center for Clinical Epidemiology and Biostatistics, 836 Blockley Hall, 422 Guardian Drive, Philadelphia, PA 19104

Byung Joo Park
Department of Preventive Medicine, Seoul National University College of Medicine, 28 Yongon-Dong, Chongro-Gu, Seoul 110-799, Korea

K. Haynes
HealthCore, Inc., Wilmington, USA

K. Hori
Hamamatsu University School of Medicine, Japan

D. Horton
Institute for Health, Health Care Policy and Aging Research, Rutgers

R. A. Hubbard
Perelman School of Medicine, University of Pennsylvania, USA

K. Huybrechts
Brigham & Women's Hospital, Department of Medicine, USA

J. Jose
School of Pharmacy, University of Nizwa, Oman

S.-Y. Jung
College of Pharmacy, Chung-Ang University, Korea

Y.-H. Kao Yang
National Cheng Kung University, Tainan, Taiwan

O. H. Klungel
Utrecht University, Utrecht, The Netherlands

K. Kubota
Faculty of Medicine, University of Tokyo, Japan

E.-C. Lee
National Cheng Kung University, Tainan, Taiwan

J. Lee
Division of Clinical Epidemiology, Seoul National University Hospital, Korea

S.-M. Lee
Chung-Ang University College of Pharmacy, Seoul, Korea

C. Leonard
Perelman School of Medicine, University of Pennsylvania, USA

E. Lowenthal
Perelman School of Medicine, University of Pennsylvania, USA

R. Haque*
Kaiser Permanente Southern California, Pasadena, CA, USA

D. A. Henry
ICES, Toronto, Canada

S. Hernández-Díaz
Harvard School of Public Health, USA

J. K. Jones
The Deegge Group Ltd., USA

D. Layton
Drug Safety Research Unit, Southampton, UK

Adrian Levy*
Dalhousie University, Halifax, Canada

R. Martin
University of Bristol, UK

A. D. McMahon
Glasgow University Dental School, UK

R. H. B. Meyboom
The Uppsala Monitoring Centre, Sweden

D. Mines*
Merrick & Co., North Wales, PA, USA

J. L. Montastruc
Hôpitaux de Toulouse, Faculté de Médecine, Toulouse, France

N. Moore
Université Victor Segalen, France

R. Platt
Harvard Medical School, Boston, MA, USA

R. Platt
McGill University, Montreal, Canada

R. Mamtani
Perelman School of Medicine, University of Pennsylvania, USA

N. Roy
School of Pharmacy and Medical Sciences, University of South Australia, Australia

M. B. Ritchey
RTI Health Solutions, USA

E. E. Roughhead
University of South Australia, Australia

J. Roy
Perelman School of Medicine, University of Pennsylvania, USA

J.-Y. Shin
School of Pharmacy, Sungkyunkwan University, Korea

H. J. Song
Hallym University College of Medicine, Korea

A. J. Stephens-Shields
Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania Perelman School of Medicine, PA, USA

J. Takeshita
Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania Perelman School of Medicine, PA, USA

D. Toh
Harvard Medical School and Harvard Pilgrim Health

B. L. VanderBeek
Perelman School of Medicine, University of Pennsylvania, USA

A. Willis
Perelman School of Medicine, University of Pennsylvania, USA

J. Young Kim
Department of Family Medicine, Seoul National University Bugdon Hospital, Korea

L. Post*
Australian Institute of Health Innovation, Macquarie University, North Ryde, NSW, Australia

J. Raine
MHR A, London, UK

S. Schneeweiss
Harvard Medical School, Boston, MA, USA

M. Schulz*
Freie Universität Berlin/German Institute for Drug Use Evaluation (DAPI), Berlin, Germany

J. D. Seeger*
Optum, Waltham MA, USA

S. Setoguchi
Rutgers University, NJ, USA

R. Shah
Gerrards Cross, UK

S. Shaker
Drug Safety Research Unit, Southampton, UK

G. Siddhar* HealthCore Inc., Alexandria, VA, USA

S. Sissa
McGill University and Royal Victoria Hospital, Montreal, Canada

M. Tadrous*
St Michael's Hospital, Toronto, Canada

G. Trifirò*
University of Messina, Italy

C. Varas-Lorenzo
RTI Health Solutions, Spain

A. M. Walker
Harvard School of Public Health, Boston, MA, USA

*ISPE Representatives to the Editorial Board
INSTRUCTIONS TO AUTHORS

These instructions are abridged. Full instructions are published on the Journal’s website — http://wileyonlinelibrary.com/journal/pds. Click the link for ‘author guidelines.’ Authors are strongly advised to read the full instructions online prior to submitting.

1. AIMS AND SCOPE

The aim of Pharmacoepidemiology and Drug Safety is to provide an international forum for the communication and evaluation of data, methods and opinion in the discipline of pharmacoepidemiology, defined broadly.

Particular areas of interest include:

- design, analysis, results, and interpretation of studies looking at the benefit or safety of specific pharmaceuticals, biologics, or medical devices, including studies in pharmaco vigilance, postmarketing surveillance, pharmaco economics, patient safety, molecular pharmacoepidemiology, or any other study within the broad field of pharmacoepidemiology;
- comparative effectiveness research relating to pharmaceuticals, biologics, and medical devices. Comparative effectiveness research is the generation and synthesis of evidence that compares the benefits and harms of alternative methods to prevent, diagnose, treat, and monitor a clinical condition, as these methods are truly used in the real world;
- methodologic contributions of relevance to pharmacoepidemiology, whether original contributions, reviews of existing methods, or tutorials for how to apply the methods of pharmacoepidemiology;
- assessments of harm versus benefit in drug therapy;
- patterns of drug utilization;
- relationships between pharmacoepidemiology and the formulation and interpretation of regulatory guidelines;
- evaluations of risk management plans and programmes relating to pharmaceuticals, biologics and medical devices.

2. MANUSCRIPT CATEGORIES

Pharmacoepidemiology and Drug Safety invites the following types of submission:

Original Reports — Original Reports are the Journal’s primary mode of scientific communication. Original Reports typically do not exceed 3,000 words of body text, excluding abstract, tables, figures and references.

Reviews — Reviews of ‘hot topics’ and controversies are welcome. Reviews should be of a critical nature, discussing all sides of a question in a balanced manner. Experts considering offering such a review should feel free to contact either of the Editors, as appropriate, in order to avoid unnecessary effort. All reviews will be peer-reviewed. Reviews typically should not exceed 3,000 words of body text (excluding abstract, figures, tables and references), and be limited to 150 references.

Brief Reports — Succinct data papers, and in highly unusual situations case reports (Pharmacoepidemiol Drug Saf 2007;16:473), will be considered for publication as Brief Reports. Brief Reports should not exceed 1,500 words, and be limited to 1 table, 1 figure and 15 references.

Commentaries — Commentaries cover a variety of topics of current interest in pharmacoepidemiology and pharmaco vigilance, and the intersection between these disciplines and society. The Journal welcomes submissions and proposals. Commentaries are limited to 1,500 words and 15 references.

Letters to the Editor — Letters to the Editor are encouraged, and may be in response to issues arising from recently published articles, or short, free-standing pieces expressing an opinion. No abstract is required, and text should be formatted in one continuous section. Letters are limited to 1000 words.

Research Protocols — See online for specific criteria for submission.

Other — Reviews of books and other media may be submitted only at the invitation of the Editors. However, suggestions are welcome.

3. EDITORS AND PEER REVIEW

The Editor-in-Chief, Brian Strom (email: bstrom@upenn.edu), will apportion manuscripts to a Regional Editor based on location unless there are conflicts of interest between the paper’s authors and that regional office.

Papers from Americas will be handled by:
Vincent Lo Re—University of Pennsylvania Perelman School of Medicine, Philadelphia, PA USA.
E-mail: vincentl@pennmedicine.upenn.edu

Papers from Europe will be handled by:
Hubert Leufkens—Utrecht University, Faculty of Science Utrecht Institute for Pharmaceutical Sciences (UIPS)
Division of Pharmacoepidemiology and Clinical Pharmacology
PO Box 80 082, 3508 TB Utrecht, The Netherlands
E-mail: H.G.M.Leufkens@uu.nl

Papers from Asia, Africa, the Middle East, and Oceania will be handled by:
Byung Joo Park—Seoul National University College of Medicine, Seoul, Korea
E-mail: bjpark@snu.ac.kr

A fast-track review and publication process is in place for particularly time-sensitive findings of urgent public health importance. The Editor-in-Chief should be contacted to begin this process.

4. SUBMISSION OF MANUSCRIPTS

All submissions should be made online at the Pharmacoepidemiology and Drug Safety Manuscript Central site—http://mc.manuscriptcentral.com/pds. New users should first create an account. Once a user is logged onto the site, submissions should be made via the ‘Author Centre’.
REVIEWS

899 Identification and mapping of worldwide sources of generic real-world data

906 Use of real-world evidence from healthcare utilization data to evaluate drug safety during pregnancy
K. F. Huybrechts, B. T. Bateman and S. Hernández-Díaz

ORIGINAL REPORTS

923 Methods to generate and validate a Pregnancy Register in the UK Clinical Practice Research Datalink primary care database
C. Minassian, R. Williams, W. H. Meeraus, L. Smeeth, O. M. R. Campbell and S. L. Thomas

934 A tool for empirical equipoise assessment in multigroup comparative effectiveness research

942 Incidence, risk factors, and outcomes of warfarin-associated major bleeding in Thai population
W. Priksri, W. Rattanavipanon, W. Saechar, T. Tanyasaenook, A. Phrommintikul, S. Chulavatnatol and S. Nathisuwan

951 Assessment of ICD-10-CM code assignment validity for case finding of outpatient anticoagulant-related bleeding among Medicare beneficiaries

LETTER TO THE EDITOR

1032 Comment on “How pharmacoepidemiology networks can manage distributed analyses to improve replicability and transparency and minimize bias”
M. J. Schuemie, D. Madigan, P. B. Ryan, C. Reich, M. A. Suchard, J. A. Berlin and G. Hripcsak